Mesoblast LimitedMESO

Health Care · Pharmaceuticals, Biotechnology & Life Sciences · NASDAQ · Australia · mesoblast.com

Mesoblast Limited develops allogeneic (off-the-shelf) cellular medicines for severe and life-threatening inflammatory conditions, using a proprietary mesenchymal lineage cell therapy platform. Its Ryoncil (remestemcel-L-rknd) for steroid-refractory acute graft versus host disease in pediatric patients is the first FDA-approved mesenchymal stromal cell therapy; rexlemestrocel-L is in development for heart failure and chronic low back pain. Listed on the ASX (MSB) and Nasdaq (MESO).

Key ratios

FCF / Sales

-37.1%2026

2025 -294.4%2024 -825.6%

Net margin

-47.8%TTM

2026 -47.8%

ROA

-4.1%2026

2025 -5.4%2024 -5.4%

ROE

-9.9%TTM

2026 -9.9%2025 -19.0%2024 -17.9%

Revenue growth

599.2%TTM

2026 599.2%2025 191.4%2024 -21.3%

Recent news

Mesoblast Reports Substantial Revenue Growth to US$120M 2026-08-27 · GlobeNewswire Mesoblast Financial Results and Corporate Update Webcast 2026-08-24 · GlobeNewswire Mesoblast Achieves Major Milestone Completing Patient Treatment in Pivotal Phase 3 Trial for Chronic Low Back Pain 2026-08-17 · GlobeNewswire

Track MESO in your journal

Save it to a watchlist, run a reverse DCF, and keep your notes on the company in one place. Free to start.

Create a free account

Figures are sourced from third parties and shown for research only. They may be delayed or incomplete, and nothing on this page is investment advice or a recommendation to buy or sell. Read the full disclaimer